Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
about
Quetiapine versus other atypical antipsychotics for schizophreniaAntipsychotic drug treatment for elderly people with late-onset schizophreniaZiprasidone versus other atypical antipsychotics for schizophreniaMetabolic issues in patients affected by schizophrenia: clinical characteristics and medical managementReview of the evidence: prevalence of medical conditions in the United States population with serious mental illnessCan exercise increase fitness and reduce weight in patients with schizophrenia and depression?Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysisNew developments in the management of schizophrenia and bipolar disorder: potential use of cariprazineSchizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models.Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health AdministrationMetabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general populationProtection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms.Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden.Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit.Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expressionSTRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications.Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disordersProtocol for CHANGE: a randomized clinical trial assessing lifestyle coaching plus care coordination versus care coordination alone versus treatment as usual to reduce risks of cardiovascular disease in adults with schizophrenia and abdominal obesitThe other 23 hours: a qualitative study of fitness provider perspectives on social support for health promotion for adults with mental illness.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.Weight maintenance following the STRIDE lifestyle intervention for individuals taking antipsychotic medications.Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia.Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluationA comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practiceThe CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesiSequential behavioral treatment of smoking and weight control in bipolar disorder.Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia.Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United StatesThe association between weight change and symptom reduction in the CATIE schizophrenia trial.Predictors of antipsychotic dose changes in the CATIE schizophrenia trialRoles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists.Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
P2860
Q24202427-DCD79CDF-8FB0-41F9-B8D1-DDA1B420A7FBQ24203649-F9F1FB47-C3E2-4878-8E9A-67D083AF7A13Q24240260-6E547079-3397-4F2B-8E25-727D0F7A6CC8Q26783003-726AB94C-87AB-467E-B16A-C24AC9203D1CQ26849474-80A3C210-163E-4403-B0AB-968EA8DD5BA8Q27023984-0D7502A7-BDDA-4BE8-928A-80F74B4CB9E0Q28066750-A217A538-4282-4865-8A16-30D59CDD3157Q28083061-F2CA5DB2-DE5B-4F29-8A67-B144717F52EAQ30416883-CAC0047F-A7F6-43E0-A4A2-EB293F622593Q33519730-41E3CA3C-63E6-429B-98C4-17F0E3D770A3Q33622056-298DB7B3-B068-4BF6-93A2-DC201381DEFDQ33912482-9D3413C8-0B2B-48F5-B912-4C1F43529A6BQ34183495-04CB3B52-CCD0-4138-8EF7-7EAD5697465AQ34213209-3326CC5C-C89A-4EE5-B35C-BF42F1ECA19EQ34543401-ECCDC48A-23BB-41BA-A2F5-0C0F952A67F4Q34571634-07E52A52-AE82-4704-8C07-C9A81F470213Q34613195-9883C1FE-68F0-4C80-A2C1-1CE29F40DFD8Q34623350-5EAAC745-1FF9-4D46-8A59-B01A45E3CFE9Q34646095-1E293AC7-2CF1-4E77-8151-3FF2F1EA61F7Q34786258-F80C1227-DA25-47F5-813B-148DF5A6605DQ35000399-186511CD-705E-4855-B039-653038C4E771Q35001376-B7CA4B46-E128-4904-818A-37CC5587A25FQ35334500-0F96894E-F418-4669-ABF5-5447E7629135Q35700367-5C189FEE-38CD-4D63-8F89-1E159A1BBCEAQ35715547-4F8D223E-2A35-4293-AD7F-2851F4001889Q36063735-36633908-8373-4047-B4B8-876F57213595Q36101578-3AF90B33-2DBE-4376-9FE6-A23718202916Q36555343-A2D44D6A-8B22-4AF3-AD9F-74F4E05CE375Q36756154-A52D9646-43E4-4CC7-99F5-772E0E227241Q36771558-A09BAFC2-309C-4DD8-876E-D819F9D54D8EQ36843480-F4A0ABD7-24E2-4A2F-BE69-F5A59856F4C4Q37015355-40EB11A1-E873-49EE-9ED8-8BE4FAE91311Q37031181-0D8E2969-7AD1-46C3-97C2-F786832087D1Q37091453-5C311C76-F909-478A-B36E-2DF89DCA67C2Q37110540-10C10B65-FCB5-416B-B755-DF39E1E070F4Q37185914-841BB7C7-678F-4F2E-9119-7D80FE21723AQ37212106-79365DDD-5270-4220-AA84-3CF943C27B8AQ37212114-CAD2C663-8C57-44A3-AB13-A740FC283C94Q37296552-00C019ED-8C27-40F4-B2D1-3B7E000D71DEQ37416813-3534D0B1-027D-48C7-8E15-8D906799E254
P2860
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antipsychotic effects on estim ...... the CATIE schizophrenia study.
@en
Antipsychotic effects on estim ...... the CATIE schizophrenia study.
@nl
type
label
Antipsychotic effects on estim ...... the CATIE schizophrenia study.
@en
Antipsychotic effects on estim ...... the CATIE schizophrenia study.
@nl
prefLabel
Antipsychotic effects on estim ...... the CATIE schizophrenia study.
@en
Antipsychotic effects on estim ...... the CATIE schizophrenia study.
@nl
P2093
P2860
P1476
Antipsychotic effects on estim ...... the CATIE schizophrenia study.
@en
P2093
Gail L Daumit
Henry A Nasrallah
Jeffrey A Lieberman
John K Hsiao
Jonathan M Meyer
Joseph P McEvoy
Sonia M Davis
T Scott Stroup
Vicki G Davis
P2860
P304
P356
10.1016/J.SCHRES.2008.07.006
P407
P577
2008-09-04T00:00:00Z